FDA approves pan-tumour genomic profiling... Roche company Foundation Medicine Inc. (FMI) has been granted FDA approval for a diagnostic multiplex tumour profiling assay, which identifies a broad range of tumour markers in one single measurement. more ➔
Sanofi Pasteur ends Clostridium difficile...The decision of the vaccine arm of French drug giant Sanofi was based on an independent interim analysis of a pivotal Phase III study enroling up to 16,500 people at risk of Clostridium difficile infection … more ➔
Shire expands orphan drug portfolioShire has received FDA Orphan Drug Status for its anti-MAdCAM Antibody SHP647 to treat pediatric ulverative colitis. more ➔
Speeding up digital transformation in the...845 medical affairs and biopharma industry professionals at Veeva Commercial & Medical Summit Europe in Madrid discussed how digitalisation can speed up the development of new medical … more ➔
Biocartis raises €80mBelgian liquid biopsy specialist Biocartis Group NV has pocketed €80m through an equity placement by offering 6.4 million new shares. more ➔
Global Bioenergies delivers first batch of...French green chemistry specialist Global Bioenergies announced the delivery of a first batch of sustainable cosmetic ingredients to cosmetics heavyweight L’Oréal. It was produced as part of the ISOPROD … more ➔
EuropaBio names top EU biotech SMEs Three innovative biotech companies have baged the prestigious EuropaBio SME Awards for their innovative business models. more ➔
Tumour-associated bacteria co-migrate to m...The same bacteria present in primary tumours of patients with colorectal cancer are also present in liver metastases, according to a new study. Whats more, presence of the bacteria was found to correlate … more ➔
Philips leads €6.3m EU liquid biopsy con...The EU is investing another €6.3m into the blood diagnosis of primary breast cancer and rectal cancer. In the 4-year LIMA project, Royal Philips will lead a SME consortium that combines liquid … more ➔
Heidelberg Pharma AG raises €34.4mAntibody-drug-conjugate (ADC) specialist Heidelberg Pharma AG has raised €34.4m through the issuance of 7,484,190 new shares at €2.60 and 14,968,380 convertible bonds with a nominal value of €1 … more ➔